Editorial: Aprotinin and vein graft occlusion - The controversy continues

Journal of Thoracic and Cardiovascular Surgery

Volumn 116, Issue 5, 1998, Pages 731-733

  Westaby, S ^a   Katsumata, T ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APROTININ; HEPARIN; HEMOSTATIC AGENT;

ANGIOGRAPHY; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GRAFT OCCLUSION; HUMAN; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; VEIN GRAFT; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY BYPASS GRAFT; HEART INFARCTION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TRANSPLANTATION; VEIN;

APROTININ; CORONARY ARTERY BYPASS; GRAFT OCCLUSION, VASCULAR; HEMOSTATICS; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL RATE; VEINS;

EID: 0032209339     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(98)00457-7     Document Type: Article

References (16)

1. S Westaby Aprotinin in perspective Ann Thorac Surg 55 1993 1033 1041
2. EM Boyle Jr ST Lille E Allaire AW Clowes ED Verrier Endothelial cell injury in cardiovascular surgery: atherosclerosis Ann Thorac Surg 63 1997 885 894
3. S Goldman J Copeland T Moritz Improvements in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Co-operative Study Circulation 77 1988 1324 1332
4. W Dietrich G Dilthey M Spannagl Influence of high dose aprotinin on anticoagulation, heparin requirements, and celite and kaolin activated clotting time in heparin pre-treated patients undergoing open heart surgery Anesthesiology 83 1995 679 689
5. V Umbrain F Christiaens F Camu Intraoperative coronary thrombosis: Can aprotinin and protamine be incriminated? J Cardiothoracic Vasc Anesth 8 1994 198 201
6. J Van der Meer HL Hillege CA Ascoop Aprotinin in aorto-coronary bypass surgery: Increased risk of vein graft occlusion and myocardial infarction? Supportive evidence from a retrospective study Thromb Haemost 75 1996 1 3
7. DM Cosgrove B Heric BW Lytle Aprotinin therapy for reoperative myocardial revascularization: a placebo controlled study Ann Thorac Surg 54 1992 1031 1038
8. JH Levy R Pifarré HV Schaff A multicenter, double blind, placebo controlled trial of aprotinin for reducing blood loss and the requirement for donor blood transfusion in patients undergoing repeat coronary artery bypass grafting Circulation 92 1995 2236 2244
9. JH Lemmer Jr EW Dilling JR Morton Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens Ann Thorac Surg 62 1996 1659 1668
10. PK Smith LH Muhlbaier Aprotinin: safe and effective only with the full-dose regimen Ann Thorac Surg 62 1996 1575 1577
11. BP Bidstrup SR Underwood RN Sapsford EM Streets Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency J Thorac Cardiovasc Surg 105 1993 934 942
12. M Lass A Welz M Kochs Aprotinin in elective primary bypass surgery: graft patency and clinical efficacy Eur J Cardiothorac Surg 9 1995 206 210
13. N Hayashida T Isomura T Sato Effects of minimal dose aprotinin on coronary artery bypass grafting J Thorac Cardiovasc Surg 114 1997 261 269
14. M Havel F Grabenwoger J Schneider Aprotinin does not decrease early graft patency after coronary bypass grafting despite reducing postoperative bleeding and use of donated blood J Thorac Cardiovasc Surg 107 1994 807 810
15. EL Alderman HJ Levy JB Rich M Nili B Vidne H Schaff Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial J Thorac Cardiovasc Surg 116 1998 716 730
16. Bayer advertising literature for Trasylol J Thorac Cardiovasc Surg 114 2 1998 22A